✦ LIBER ✦

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

✍ Scribed by Morris D. Groves; Vinay K. Puduvalli; Susan M. Chang; Charles A. Conrad; Mark R. Gilbert; Ivo W. Tremont-Lukats; Ta-Jen Liu; Pamela Peterson; David Schiff; Timothy F. Cloughesy; Patrick Y. Wen; Harry Greenberg; Lauren E. Abrey; Lisa M. DeAngelis; Kenneth R. Hess; Kathleen R. Lamborn; Michael D. Prados; W. K. Alfred Yung

Publisher: Springer US
Year: 2006
Tongue: English
Weight: 166 KB
Volume: 81
Category: Article
ISSN: 0167-594X
DOI: 10.1007/s11060-006-9225-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II clinical trial of poly-ICLC w

A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)

✍ Nicholas Butowski; Susan M. Chang; Larry Junck; Lisa M. DeAngelis; Lauren Abrey; 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 181 KB

Phase II study of neoadjuvant 1, 3-bis (

Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma : A North American Brain Tumor Consortium trial

✍ Susan M. Chang; Michael D. Prados; W. K. Alfred Yung; Howard Fine; Larry Junck; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract ## BACKGROUND Temozolomide (TMZ) and 1, 3‐bis (2‐chloroethyl)‐1‐nitrosourea (BCNU) are reported to be active agents in anaplastic glioma (AG). TMZ has also been shown to deplete alkyltransferase, a DNA repair enzyme that contributes to nitrosourea resistance. The objective of the curre